BackAvecho Biotechnology Limited Overview

Avecho Biotechnology Limited Other Current Liabilities

Latest other current liabilities for AVEFF: $500K.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$503559.00
↓ 38.04% YoYΔ $-309096.00 vs prior year quarter

Peer trimmed avg / median

Loading

Avecho Biotechnology Limited Other Current Liabilities History

Loading

Avecho Biotechnology Limited vs. peers: Other Current Liabilities Comparison

Loading

Avecho Biotechnology Limited Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Avecho Biotechnology Limited (AVEFF) FAQ

As of the most recent data (June 2026), AVEFF shows a other current liabilities of $500K. That compares with $810K in the prior-year period — down 38.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AVEFF's other current liabilities is now $500K (was $810K) — a 38.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Avecho Biotechnology Limited is outperforming or lagging.

Tracking AVEFF's other current liabilities over time shows whether Avecho Biotechnology Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $500K That compares with $810K in the prior-year period — down 38.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Avecho Biotechnology Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $500K) with ownership activity and broader fundamentals.

Avecho Biotechnology Limited's other current liabilities is $500K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.